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Objectives This study sought to investigate plasma levels of circulating cardiac natriuretic peptides, atrial natriuretic peptide
(ANP) and B-type or brain natriuretic peptide (BNP), in the general community, focusing on their relative differ-
ences in worsening human hypertension.
Background Although ANP and BNP are well-characterized regulators of blood pressure in humans, little is known at the pop-
ulation level about their relationship with hypertension. The authors hypothesized that hypertension is associ-
ated with a lack of activation of these hormones or their molecular precursors.
Methods The study cohort (N  2,082, age 45 years) was derived from a random sample from Rochester, Minnesota,
and each subject had a medical history, clinical examination, and assessment of different plasma forms of ANP
and BNP. Patients were stratified by blood pressure. Multivariable linear regression was used to assess differ-
ences in natriuretic peptide levels in worsening hypertension.
Results Compared to normotensive, BNP1–32 and N-terminal proBNP1–76 (NT-proBNP1–76) were significantly decreased in
pre-hypertension (p  0.05), with BNP1–32 significantly decreased in stage 1 as well (p  0.05). Although
proBNP1–108 remained unchanged, the processed form was significantly increased only in stage 2 hypertension
(p  0.05). ANP1–28 remained unchanged, while NT-ANP1–98 was reduced in pre-hypertension (p  0.05).
Conclusions The authors demonstrated the existence of an impaired production and/or release of proBNP1–108 along with a
concomitant reduction of BNP1–32 and NT-proBNP1–76 in the early stages of hypertension, with a significant ele-
vation only in stage 2 hypertension. Importantly, they simultaneously demonstrated a lack of compensatory ANP
elevation in advanced hypertension. (J Am Coll Cardiol 2012;60:1558–65) © 2012 by the American College of
Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.05.049s
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uAtrial natriuretic peptide 1–28 (ANP) and B-type natri-
uretic peptide 1–32 (BNP1–32) are 28- and 32-amino acid
ormones, respectively, that are normally produced and
ecreted by the human heart in response to cardiac injury
nd mechanical stretch. Both cardiac hormones regulate
lood pressure (BP) homeostasis via their pleiotropic
ctions, including natriuresis, vasodilation, and renin-angiotensin-
ldosterone system suppression, but their mechanisms of
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1,2). ANP is secreted and circulates as an active hormone,
hereas a growing body of evidence indicates that the major
ecreted and circulating immunoreactive form of BNP is
ctually its 108-amino acid precursor, pro–B-type natri-
retic peptide1–108 (proBNP1–108), and not BNP1–32 (3–
6). Current evidence supports that this circulating prohor-
mone, which has significantly reduced biological activity, is
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BNP1–32 and the inactive N-terminal proBNP1–76 (NT-
roBNP1–76) in plasma or at the target tissue level (3,7,8).
Although the ANP and BNP systems have been studied exten-
sively, their simultaneous critical role in BP regulation has not yet
been described at the population level.
Prior studies have reported that BNP1–32 and NT-
roBNP1–76 are elevated in hypertension, especially when
eft ventricular hypertrophy (LVH) is present (9). However,
elluardo et al. (10) challenged this common view by
howing in clinically and biochemically well-characterized
ubjects with essential hypertension that BNP1–32 and
NT-proBNP1–76 are actually reduced in the early stages of
uman hypertension. Furthermore, the importance of ANP
nd BNP in BP regulation and in risk for development of
ypertension was recently confirmed by the elegant studies
f Newton-Cheh et al. (11). In that population study,
enetic variants of the ANP and BNP gene, resulting in
igher plasma concentrations of ANP and/or BNP, were
ssociated with lower BP and reduced risk for hypertension.
hese findings are consistent with earlier animal studies in
hich ANP or natriuretic peptide receptor type A (NPR-A)
ene deletion in mice resulted in hypertension and marked
VH and hypertension (12). Nonetheless, it is unknown
hether decreased BNP1–32 is accompanied by reduced circu-
ating proBNP1–108 and ANP, which, if present, would indicate
hat inadequate natriuretic peptide synthesis or secretion is a
ignificant mechanism contributing to hypertension develop-
ent. A lack of large, complete biomarker studies in hyper-
ensive patients, with and without end-organ damage, has
imited our understanding of the role of these 2 cardiac
eptides (ANP and BNP) in worsening hypertension.
Using a large study from Olmsted County, Minnesota,
erived from a population-based sample known as the
AVD (Prevalence of Asymptomatic Ventricular Dysfunc-
ion) cohort (N  2,082, age 45 years), our objective was
o confirm and extend in the general adult population our
revious assessment of circulating levels of several molecular
orms of BNP and ANP through simultaneous measurement
f proBNP1–108, BNP1–32, NT-proBNP1–108, ANP1–28, and
NT-ANP1–98. As a corollary to the first observation of
Belluardo et al. (10), we hypothesized that human hyper-
tension is characterized by a lack of activation of these
cardiac hormones, indicating the existence of a relative
deficiency of their endogenous cardiorenal protective actions
in this morbid condition. This finding would underscore an
opportunity to intervene in hypertension, with improved
therapeutics including natriuretic peptides and their chime-
rics, which are currently in the pipeline for clinical trials.
Methods
Study population. This study was approved by the Mayo
Clinic institutional review board, and informed consent was
obtained from all subjects. Participating subjects came from
the PAVD cohort (N  2,082, age 45 years), a studypopulation derived from a ran-
dom sample of subjects from the
Rochester Epidemiology Project
(13–15). PAVD investigators
have previously reported each
subject’s medical history, clinical
examination, detailed 2-dimensional
echocardiography, and procedures
for storage and measurement of
BNP forms, including BNP1–32
(16), NT-proBNP1–76 (17), and
roBNP1–108 (5). Of note, al-
hough prior human studies used
ssays that measured BNP1–32 and
T-proBNP1–76, which cross-
reacted with proBNP1–108 (3), our
ovel approach used a newly avail-
ble radioimmunoassay that is
ighly specific for proBNP1–108
(18). Furthermore, we simultane-
ously measured 2 different forms of mature circulating ANP
(ANP1–28 and NT-proANP1–98).
Subjects were classified according to office systolic BP
and/or diastolic BP as normotensive or belonging to 1 of 3
grades of hypertension: pre-hypertensive, stage 1 hyperten-
sion, and stage 2 hypertension, in accordance with the
Seventh Report of the Joint National Committee on Pre-
vention, Detection, Evaluation, and Treatment of High
Blood Pressure (JNC 7) guidelines (19). BP was measured 3
times at 5-min intervals at an outpatient clinic. A complete
cardiovascular evaluation, including 2-dimensional Doppler
echocardiograms, was performed the day of blood collec-
tion. Heart failure was defined as previously described in the
publication from Redfield et al. (14).
LVH was defined as a LV mass index 134 for males
and 110 for females, where the LV mass index was
defined as the quotient of left ventricular mass (by echocar-
diogram) divided by the body surface area (20).
Radioimmunoassay. Natriuretic peptide levels were deter-
mined using the Shionogi (Florham Park, New Jersey) and
Biosite (San Diego, California) assays for BNP1–32, Roche
(Indianapolis, Indiana) for NT-proBNP1–76, Bio-Rad
Hercules, California) for proBNP1–108, and Phoenix Phar-
aceuticals (Mountain View, California) for ANP1–28 and
for NT-proANP1–98 (21,22). The specific characteristics of
these assays have previously been reported. The BNP1–32
and NT-proBNP1–76 assays have been reported to display
ross-reactivities for precursor BNP forms, including
roBNP1–108 (3). However, they have been found to be
ighly specific with regard to processed BNP1–32 and
T-proBNP1–76, respectively.
Statistical methods. Summary statistics were separated by
JNC 7 category as defined by BP at the time of clinical exam
and displayed as frequencies (percentages) for categorical
variables, and median, Q1 to Q3 range, and frequency
Abbreviations
and Acronyms
ANP1–28  atrial natriuretic
peptide1–28
BMI  body mass index
BNP1–32  B-type
natriuretic peptide1–32
BP  blood pressure
NT-ANP1–98  N-terminal
atrial natriuretic
peptide1–98
NT-proBNP1–76  N-terminal
pro–B-type natriuretic
peptide1–76
LV  left ventricular
LVH  left ventricular
hypertrophy
proBNP1–108  pro–B-type
natriuretic peptide1–108(percentage) of missing entries for continuous variables.
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Decreased ANP and BNP in Human Hypertension October 16, 2012:1558–65Categorical variables were compared by chi-square test, and
continuous variables (including levels of natriuretic peptide
forms) were compared by the Kruskal-Wallis rank sum test.
Multivariable linear regression was used to determine which
variables were independently associated with plasma BNP-
form levels using a step-wise model-building process. The
variables for each multivariable linear regression model were
selected from among the variables with p  0.10 in
univariate analysis (not shown). With the exception of age,
continuous variables were classified into categories. Body
mass index (BMI) was included as a 3 level variable: 25
kg/m2 (reference), 25 to 30 kg/m2, and 30 kg/m2. Cre-
tinine was defined as a dichotomous variable: 1.2 (refer-
nce) and 1.2. To account for potential non-linearity of
P effects with age, a quadratic term for age was also
ncluded. Progressive models added variables that were
ssociated with the plasma concentration of the hormones
nd a final model included age, age2, sex, BMI, LVH,
creatinine level, and the number of antihypertensive medi-
cations (except for the analysis that was performed in the
subjects who were not on antihypertensive medications). In
order to satisfy modeling and regression assumptions, BNP
and ANP values were transformed by taking the natural
logarithm of the raw values. In order to visually display
effects, the least squares adjusted means were calculated
from the final model and estimates and 95% CI were
back-transformed to original scale. Homogeneity, across
hypertension groups, of age and gender effects were tested
by inclusion of interaction terms with stage of hypertension.
Age effects were found to be homogeneous. Due to some
evidence that gender effects were non-homogeneous a
sensitivity analysis was conducted to compare normotensive
and pre-hypertensive subjects. All tests were 2-sided, and
for all analyses, p  0.05 was considered statistically
significant.
Results
General characteristics. Table 1 displays the characteris-
tics of our study population stratified by JNC 7 BP
categories at initial visit. The covariates that were signifi-
cantly different between the stages of hypertension were age,
sex, BMI, chronic renal insufficiency defined as Cockroft-
Gault calculated glomerular filtration rate 60 ml/min,
diabetes, coronary artery disease, valvular heart disease,
cerebrovascular accidents, LV mass index, LV geometry,
proBNP1–108, NT-proBNP1–76, BNP1–32, ANP1–28, and
NT-proANP1–98. Of the 2,082 subjects, 1,465 (72%) had
levated BP (systolic BP 120 mm Hg and/or diastolic BP
80 mm Hg), further classified into 755 pre-hypertensive
ubjects (51% of all hypertensive subjects), 492 stage 1 hyper-
ension (34%) subjects, and 218 stage 2 hypertension (15%)
ubjects. The overall prevalence of LVH in our study popula-
ion was 12.4%. As expected, the percentage of subjects with
VH increased over each stage of hypertension, from 7.3% inormotensive subjects to 32.9% in subjects with stage 2
ypertension.
atriuretic peptides in normotensive and in hypertensive
ubjects. Table 2 displays the effects of hypertension stage
n natriuretic peptides levels, with no adjustment and,
onsistent with previous reports, shows progressive elevation
f all NPs with the severity of hypertension. Progressive
ultivariable adjustments were performed on the entire
tudy population, including those on antihypertensive med-
cations. This regression accounted for important covariates
hat were previously identified in univariate analysis, includ-
ng age, sex, BMI, LVH, and creatinine (Fig. 1). Although,
roBNP1–108 remained unchanged in the different stages of
hypertension, processed BNP forms, including BNP1–32
and NT-proBNP1–76, were significantly decreased in pre-
ypertension (p  0.05), with BNP1–32 significantly de-
creased in stage 1 as well (p  0.05). The NT-proBNP1–75
tended to increase, while BNP1–32 was elevated in stage 2
hypertension (p  0.05). ANP1–28 levels, after adjustment,
showed no association with stage of hypertension, whereas
NT-proANP1–98 was significantly decreased in pre-
hypertension (p  0.05), and showed no change with stages
1 and 2 hypertension. These results were similar when
analyses were restricted to only normotensive and pre-
hypertensive subjects (Table 3).
Because the effect of antihypertensive medications on
natriuretic peptides levels cannot be completely corrected by
multivariate adjustment, we reanalyzed the association be-
tween natriuretic peptide levels and hypertension, limiting
our analysis to subjects who were not on antihypertensive
medications (Table 3). After adjustment, we found that
none of the BNP forms were elevated and that BNP1–32
(Roche) and NT-proBNP1–76 showed a slight trend down-
ward in early hypertension. ANP1–28 levels were not asso-
ciated with stage of hypertension, whereas NT-proANP1–98
levels were significantly decreased in pre-hypertensive sub-
jects (p  0.05) in models 1 to 3.
Although, it was not the aim of the study, potential
interactions of hypertensive stage with gender and age were
also assessed in this population. There was no evidence of
interactions with age, but there was some evidence that
there were differential effects by gender (Online Table 1).
Discussion
The purpose of the current investigation was to evaluate the
hypothesis that there is a lack of elevation of circulating
ANP and BNP in hypertension in the general population.
By characterizing hypertension as a relative deficiency state
of these cardiac peptides, we imply their key role in the
development of human hypertension and their ability, if
augmented, potentially to reduce disease burden. To test
this hypothesis, we used the PAVD population, a well-
characterized adult population from Olmsted County, Min-
nesota. We classified subjects according to their BP levels
into normotensive, pre-hypertensive, and stage 1 and stage
Demographics of the Study Population by BPTable 1 Demographics of the Study Population by BP
Variable Normotensive Pre-Hypertensive Stage 1 Hypertensive Stage 2 Hypertensive Total Population p Value
Age, yrs* 56.5 (50.3–64.8) 61.0 (53.9–69.2) 65.0 (56.9–72.7) 70.1 (62.6–77.1) 61.6 (53.5–70.5) 0.001
Females 320 (56%) 360 (48%) 251 (51%) 126 (58%) 1057 (52%) 0.006
BMI, kg/m2 26.2 (23.5–29.1) 27.9 (25.4–31.2) 28.9 (25.7–33.0) 28.3 (25.3–33.2) 27.7 (25.0–31.2) 0.001
CRF 109 (20%) 168 (23%) 155 (33%) 86 (41%) 518 (26%) 0.001
Diabetes 28 (5%) 53 (7%) 50 (10%) 19 (9%) 150 (7%) 0.010
CAD 62 (11%) 78 (10%) 68 (14%) 37 (17%) 245 (12%) 0.025
HF 13 (2%) 16 (2%) 15 (3%) 7 (3%) 51 (3%) 0.65
Atrial fibrillation 17 (3%) 39 (5%) 31 (6%) 12 (6%) 99 (5%) 0.07
Creatinine 1.2 128 (23%) 194 (26%) 148 (31%) 55 (26%) 525 (27%) 0.03
Valvular disease 62 (11%) 100 (13%) 83 (17%) 47 (22%) 292 (14%) 0.001
CVA 6 (1%) 12 (2%) 3 (1%) 13 (6%) 34 (2%) 0.001
LV mass index* 90.4 (78.5–101.4) 93.8 (81.5–108.1) 98.4 (86.1–113.7) 103.0 (87.6–125.3) 93.8 (81.9–108.7) 0.001
LV geometry 0.001
Normal 394 (78%) 387 (67%) 211 (59%) 59 (40%) 1,051 (66%)
Concentric remodeling 73 (14%) 133 (23%) 91 (25%) 41 (28%) 338 (21%)
Concentric hypertrophy 20 (4%) 29 (5%) 25 (7%) 22 (15%) 96 (6%)
Eccentric hypertrophy 17 (3%) 26 (5%) 31 (9%) 27 (18%) 101 (6%)
Antihypertensive medications 130 (25%) 260 (37%) 226 (49%) 112 (55%) 728 (39%) 0.001
Antihypertensive medications, n 0.001
0 441 (77%) 495 (66%) 266 (54%) 106 (49%) 1,308 (64%)
1 69 (12%) 163 (22%) 126 (26%) 57 (26%) 415 (20%)
2 53 (9%) 74 (10%) 68 (14%) 31 (14%) 226 (11%)
3 6 (1%) 18 (2%) 26 (5%) 22 (10%) 72 (4%)
4 2 (0%) 5 (1%) 6 (1%) 2 (1%) 15 (1%)
Beta-blocker 68 (13%) 96 (14%) 87 (19%) 44 (21%) 295 (16%) 0.005
Calcium channel blocker 16 (3%) 51 (7%) 48 (10%) 33 (16%) 148 (8%) 0.001
ACE inhibitor 35 (7%) 61 (9%) 55 (12%) 30 (15%) 181 (10%) 0.003
Diuretic 55 (11%) 118 (17%) 120 (26%) 53 (26%) 346 (18%) 0.001
Nitrate 15 (3%) 27 (4%) 17 (4%) 15 (7%) 74 (4%) 0.05
Vasodilator 10 (2%) 19 (3%) 22 (5%) 12 (6%) 63 (3%) 0.01
ARB 2 (0.4%) 13 (2%) 15 (3%) 6 (3%) 36 (2%) 0.008
ProBNP1–108 (Bio-Rad)* 17.5 (8.0–36.5) 18.0 (8.0–41.0) 21.0 (9.0–43.0) 31.0 (14.0–64.0) 20.0 (9.0–42.0) 0.001
BNP3–32 (Shionogi)* 12.9 (5.1–28.6) 13.7 (5.4–28.2) 15.8 (5.8–32.7) 23.6 (10.0–52.3) 14.6 (5.6–32.0) 0.001
BNP1–32 (Biosite Triage)* 20.7 (8.5–45.3) 21.2 (8.4–44.9) 24.6 (9.7–57.2) 51.9 (22.6–106.8) 23.6 (9.5–55.3) 0.001
NT-proBNP1–76 (Roche)* 56.3 (24.3–120.0) 59.2 (24.5–118.0) 78.1 (31.9–166.9) 142.3 (62.8–332.7) 68.3 (27.8–145.4) 0.001
ANP128 (Phoenix)* 11.0 (7.2–15.2) 11.1 (7.2–15.5) 12.3 (7.6–16.8) 14.2 (8.7–18.7) 11.6 (7.5–16.2) 0.001
NT-ANP198 (Phoenix)* 2,079.0 (1,420.0–3,023.0) 2,066.5 (1,297.0–3,112.0) 2,384.0 (1,543.0–3,512.0) 2,753.5 (1,725.5–4,242.0) 2,212.5 (1,415.0–3,281.0) 0.001
Values are n (%) or median (interquartile range). *Kruskal-Wallis test used for continuous variables; all other variables were categorical and were compared by chi-square.
ACE angiotensin-inhibiting enzyme; ANP A-type natriuretic peptide; ARB angiotensin receptor blocker; BMI body mass index; BNP B-type natriuretic peptide; BP blood pressure; CAD coronary artery disease; CRF chronic renal failure; CVA cerebrovascular
accident; HF  past heart failure diagnosis; LV  left ventricular; NT  N-terminal; ProBNP  pro–B-type natriuretic peptide.
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Decreased ANP and BNP in Human Hypertension October 16, 2012:1558–652 hypertensive. Indeed, our results, for the first time,
support the existence of such a relative deficiency state, as
indicated by the simultaneous lack of increase of proBNP1–108
and ANP1–28 in any of the hypertensive stages, concomitant
with reduced levels of BNP1–32 and NT-proBNP1–76 in
early stages of hypertension and with reduced NT-ANP
in stage 1 hypertension (Fig. 1). Importantly, we are the
Univariate Analysis of Biomarkers and Stage of HypertensionTable 2 Univariate Analysis of Biomarkers and Stage of Hypert
Hypertensive Stage
proBNP1–108 Bio-Rad
(  SE)
BNP1–32 Shionogi
(  SE)
All subjects
Normotensive Reference Reference
Pre-hypertensive 0.06 0.07 0.00 0.06
Stage I hypertensive 0.16 0.07* 0.12 0.07
Stage II hypertensive 0.61 0.09† 0.52 0.08†
Subjects not on antihypertensive
medications
Normotensive Reference Reference
Pre-hypertensive 0.03 0.07 0.04 0.07
Stage I hypertensive 0.13 0.09 0.07 0.08
Stage II hypertensive 0.50 0.12† 0.49 0.11†
Values are   SE in contrast to normotensive subjects. Logarithm of BNP/ANP values used to s
Abbreviations as in Table 1.
Figure 1 Results of Multivariable Analysis of All Subjects Adjus
Age, Gender, BMI, LVH, Creatinine, and Number of An
Figure displays least squares adjusted means for each stage of hypertension and
NT-ANP  N-terminal atrial natriuretic peptide; NT-proBNP  N-terminal pro–B-typefirst to our knowledge to show that the absence of an
increase in all BNP forms was also not accompanied by a
compensatory increase in ANP forms. A significant
elevation of a mature BNP (Biosite) form was observed
only in stage 2 hypertension.
These findings extend our previous study of a selected
group of hypertensive patients (10). That study also indi-
n
32 Biosite
 SE)
NT-proBNP1–76 Roche
(  SE)
ANP1–28 Phoenix
Pharmaceuticals
(  SE)
NT-ANP1–98 Phoenix
Pharmaceuticals
(  SE)
ference Reference Reference Reference
 0.07 0.01 0.07 0.02 0.04 0.03 0.04
 0.08* 0.33 0.08† 0.10 0.04* 0.12 0.04*
 0.10† 0.96 0.11† 0.20 0.05† 0.24 0.06†
ference Reference Reference Reference
 0.08 0.06 0.08 0.02 0.05 0.08 0.05
 0.10 0.23 0.10* 0.04 0.05 0.04 0.05
 0.14† 0.68 0.14† 0.11 0.08 0.20 0.08*
gression assumptions. *p  0.05, †p  0.001 compared with normotensive subjects.
or
ertensive Medications
iomarker. ANP  atrial natriuretic peptide; BNP  B-type natriuretic peptide;
retic peptide; ProBNP  pro–B-type natriuretic peptide.ensio
BNP1–
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October 16, 2012:1558–65 Decreased ANP and BNP in Human Hypertensioncated the presence of a BNP deficiency state in early stages
of hypertension. However, the original investigation of
Belluardo et al. (10) did not have access to proBNP1–108
levels, so it was not possible to investigate whether reduced
levels of processed forms of BNP, namely NT-proBNP1–76
and BNP1–32, in early hypertensive stages were also associ-
ated with an inadequate production/release of their precur-
sor. Importantly, in the current study, when we looked at
the entire population and adjusted for antihypertensive
medications, we demonstrated that the reduced levels of
mature BNP1–32 in early stages of hypertension were accom-
panied by a lack of activation of its precursor, proBNP1–108,
nd by a similar reduction of NT-ANP1–98. All together this
ndings support the existence of a relative deficiency of such
rotective hormonal system possibly due to an impaired release
nd/or to an elevated metabolism of the mature and biologi-
ally active forms of these cardiac hormones.
ardiac endocrine function in human hypertension. For
he first time to our knowledge, both arms of the cardiac
ndocrine system were assessed in worsening hypertension
n a large sample of the general community, adjusting for
nd-organ cardiac effects of hypertension, such as ventricu-
ar hypertrophy. Adjustment for important variables associ-
ted with natriuretic peptide levels reveals that most NP
orms tend to decrease or are significantly decreased in early
ypertension and then tend to increase only in late hyper-
ension, when we consider early and late hypertension
ndependently. Furthermore, using the JNC 7 classifica-
ions, proBNP1–108, the precursor BNP form, was not
ignificantly increased in any stage of hypertension. These
bservations point to a problem of production of substrate
proBNP1–108), rather than a problem of downstream pro-
cessing in hypertension.
Our conclusion regarding the presence of a relative
deficiency of the entire BNP system in hypertension is also
supported by recent evidence that some individuals in the
community who have an elevated level of processed BNP
forms have reduced, rather than elevated, BP. Specifically,
polymorphisms in minor alleles of the NPPA gene were
ssociated with lower BP and higher natriuretic peptide
evels in subjects with coronary artery disease, although no
Univariate and Multivariate Analysis in Normotensive and Pre-HypeTable 3 Univariate and Multivariate Analysis in Normotensive a
Biomarker
Univariate Model
(  SE)
Model 1
(  SE
Log proBNP1–108 0.06 0.07 0.07 0
Log BNP1–32 (Shionogi) 0.00 0.06 0.12 0
Log BNP1–32 (Biosite) 0.02 0.07 0.13 0
Log NT-proBNP1–76 (Roche) 0.01 0.07 0.15 0
Log ANP1–28 (Phoenix Pharmaceuticals) 0.02 0.04 0.01 0
Log NT-ANP1–98 (Phoenix Pharmaceuticals) 0.03 0.04 0.11 0
Values are   SE in contrast to normotensive subjects. Model 1  ageage2s
geage2sexBMILVHcreatinine; Model 5  hypertensionageage2sexBMILVHc
egression assumptions. *p  0.05, **p  0.001 compared with normotensive subjects.
Abbreviations as in Table 1.orrelation was seen with clinical outcome (23). Further- iore, Newton-Cheh et al. (11) also found polymorphisms of
PPA associated with higher natriuretic peptide levels and
ower rates of hypertension in the general community. We
ave built on these important studies by characterizing levels of
he precursor proBNP1–108. At this time, it is unknown
hether NPPA polymorphisms are associated with higher
evels of proBNP1–108 production. Thus, this study confirms
that in human hypertension, there is a lack of activation of both
BNP and ANP.
The question remains as to why there are inadequate or
failed metabolic compensatory mechanisms, specifically
proBNP1–108 production and processing, in hypertensive
patients. Therefore, there is a need for studies at the
molecular and tissue levels of human myocardium to eluci-
date where proBNP1–108 processing occurs in humans and
whether chronically elevated BP affects the heart’s produc-
tion of proBNP1–108 (such as through LVH) more than the
eripheral processing to BNP (in plasma or at the level of a
arget organ, such as the kidney, heart, or adipose tissue).
inally, it may be possible to prevent late changes in the
rocessing pathway by therapeutic supplementation of na-
riuretic peptides, which could reduce BP and improve
ardiorenal structure and function. Indeed, a recent study by
ataliotti et al. (24) demonstrated that early vector delivery
f a proBNP gene in spontaneously hypertensive rats, which
esulted in constitutive overexpression of BNP, was associ-
ted with decreased BP and improved cardiac structure and
unction. The beneficial effect on controlling BP was re-
ently confirmed in a patient with uncontrolled hyperten-
ion despite treatment with conventional anti-hypertensive
edication, where a small dose of subcutaneously delivered
NP induced sustained normalization of BP without the
eed for further therapy (25).
tudy limitations. An important limitation of our study is
hat it is epidemiological in nature and does not describe the
olecular abnormalities that result in aberrant natriuretic
eptide levels in hypertension. Another limitation of the
urrent study is that residual confounding factors cannot be
uled out. We used multiple linear regression to attempt to
ontrol this cross-sectional comparison for marked age and
ender differences between hypertension categories, and
ive Subjectsre-Hypertensive Subjects
Model 2
(  SE)
Model 3
(  SE)
Model 4
(  SE)
Model 5
(  SE)
0.04 0.06 0.04 0.06 0.04 0.06 0.04 0.06
0.11 0.05* 0.11 0.05* 0.11 0.05* 0.11 0.05*
0.12 0.06 0.12 0.06 0.12 0.06 0.12 0.06*
0.13 0.06* 0.14 0.06* 0.13 0.06* 0.14 0.06*
0.00 0.04 0.01 0.04 0.01 0.04 0.01 0.04
0.09 0.03* 0.08 0.04* 0.08 0.03* 0.08 0.03*
odel 2  ageage2sexBMI; Model 3  ageage2sexBMILVH; Model 4 
enumber of antihypertensive medications. ^Logarithm of BNP and ANP values used to satisfyrtensnd P
)
.06
.05*
.06*
.06*
.04
.03*
ex; M
reatininndeed some differences which were not apparent in unad-
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statistical adjustment procedure makes assumptions of lin-
earity relating age and sex to log transformed peptide levels.
We tested for non-linearity of age effects as well as for
non-homogenous effects of these variables across hyperten-
sion categories. Although gender/hypertension category in-
teractions were seen, a meta analysis based on gender
stratified analysis gave very similar results to those presented
using the simpler assumption. When we examined all
hypertensive groups for evidence of interaction with age and
gender, there was some evidence of gender effects that were
differential by hypertensive stage. There was no evidence of
differences by age, however. Table 1 of the Supplementary
ata compares results of a simple gender adjustment with
he results of combining separate male and female analyses
ith meta-analysis. These data indicate that circulating
evels of NPs may be differently affected by gender.
Our study raises an important question regarding which
art of the BNP system, the production of proBNP1–108 or
he processing into mature BNP1–32, is more deficient in
ypertension, and therefore, which of the 2 could be a better
ovel therapeutic target for the treatment of hypertension.
nother important limitation is that we did not differentiate
etween essential hypertension and secondary hypertension.
e also did not differentiate between the types of antihy-
ertensive medications used in our analysis, and it may be
hat some individuals respond differently to different anti-
ypertensive agents or may seek treatment at different
oints in the course of disease, making them more or less
ikely to benefit from their own endogenous natriuretic
ystem. There is no definitive way to correct for medication
sage, and we have, therefore, performed a variety of
nalyses to attempt to adjust for this factor. Specifically, we
erformed the analysis without adjusting for medications
Table 3, models 1 to 4), and adjusting for the medications
Fig. 1, Table 3, model 5), and also in the group of subjects
ho were not taking any medication (Table 4).
erspective. Recent reports have described an underacti-
ation of BNP forms in early hypertension. A seminal study
y Newton-Cheh et al. (11) has now established in a cohort
f 48,939 subjects that basal BP and risk for hypertension is
ssociated with common genetic variants of the ANP
Univariate and Multivariate Analysis in Normotensive and Pre-HypeNot on Antihypertension MedicationsTable 4 Univariate and Multivariate Analysis in Normotensive aNot on Antihypertension Medications
Biomarker Univariate Model (  SE) M
Log proBNP1–108 0.03 0.07
Log BNP1–32 (Shionogi) 0.04 0.07
Log BNP1–32 (Biosite) 0.06 0.08
Log NT-proBNP1–76 (Roche) 0.06 0.08
Log ANP1–28 (Phoenix Pharmaceuticals) 0.02 0.05
Log NT-ANP1–98 (Phoenix Pharmaceuticals) 0.08 0.05
Values are   SE in contrast to normotensive subjects. Model 1  ageage2s
geage2sexBMILVHcreatinine. Logarithm of BNP and ANP values used to satisfy regress
Abbreviations as in Table 1.NPPA) and BNP (NPPB) genes that affect ANP and BNPevels. In that study, reduced ANP and BNP levels were
haracterized by elevated BP and increased risk for hyper-
ension, leading the authors to propose the use of novel
atriuretic peptides to treat hypertension. Furthermore, the
resence of the single nucleotide polymorphism rs5068,
haracterized by a significantly higher level of circulating
NP and BNP, was associated with a 15% reduction in
dds of hypertension. Thus, our data from a general adult
opulation and the genetic studies from Newton-Cheh et
l. support the existence of genetic predisposition to hyper-
ension that is characterized by lower circulating levels of
NP and BNP. Newton-Cheh et al. have further proposed
he beneficial effects of exogenous natriuretic peptides ad-
inistration in the regulation of BP and support the need
or their supplementation in hypertension. Recent studies
rom our group have confirmed such hypothesis both in
nimal models of hypertension and in a pilot study in
uman with uncontrolled hypertension (24,25). Indeed, the
ack of ANP and BNP functionality, whether due to
mpaired processing or production, in patients in whom
heir biological properties would be highly beneficial, may
ave clinical and therapeutic implications that favor the use
f such peptides for the treatment of this morbid condition.
n this regard, Cataliotti et al. recently reported the
avorable BP-lowering effects of subcutaneously (SQ) ad-
inistered BNP in a patient with difficult to control
ypertension and resistance to multiple drug regiment. Here
small dose of SQ BNP (10 g/kg, twice daily) completely
ormalize BP without the need of further supplementation
ith conventional antihypertensive drugs (25). This study is
he first clinical evidence of the efficacious blood pressure
ontrol with a cardiac hormone in a patient with difficult to
ontrol hypertension and opens to the possible use of BNP
or the treatment of resistant hypertension.
onclusions
e reported that although there appears to be no increase
n mature forms of ANP and BNP in early hypertension,
ultivariable modeling instead shows significant deficiency
f mature forms with a trend toward reduced proBNP1–108.
We conclude that secretion of proBNP1–108 is spared in
ive Subjectsre-Hyperten ive Subjects
(  SE) Model 2 (  SE) Model 3 (  SE) Model 4 (  SE)
 0.07 0.02 0.07 0.02 0.07 0.02 0.07
 0.06 0.00 0.06 0.00 0.06 0.00 0.06
 0.07 0.05 0.07 0.05 0.07 0.05 0.07
 0.07 0.06 0.07 0.06 0.07 0.06 0.07
 0.05 0.03 0.05 0.03 0.05 0.03 0.05
 0.04* 0.10 0.04* 0.09 0.04* 0.08 0.04
odel 2  ageage2sexBMI; Model 3  ageage2sexBMILVH; Model 4 
umptions. *p  0.05.rtensnd P
odel 1
0.00
0.01
0.07
0.08
0.01
0.12
ex; Mearly hypertension, and that it does not increase with the
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October 16, 2012:1558–65 Decreased ANP and BNP in Human Hypertensionseverity of hypertension, thus decreased levels of mature
forms of BNP are better explained by either an impaired
peripheral processing or an accelerated metabolism in this
early stage, although a relative deficiency of proBNP1–108
production does emerge as hypertension progresses, with
compensatory processing likely only in late-stage hyperten-
sion. Because LVH represents reversible end-organ damage
due to essential hypertension, which is likely the single
biggest modifiable risk factor for cardiac and renal disease
(26), the current findings encourage further studies to
evaluate whether the use of natriuretic peptides or their
chimeric derivates can be useful in the treatment of human
hypertension.
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